Parkinson’s psychosis refers to psychotic symptoms such as illusions,
hallucinations, and delusions that are frequently referred to as
‘positive,’ meaning a benefit. Quetiapine was the most commonly used
initial atypical antipsychotic medicine for therapy, followed by
Risperidone, Olanzapine, Aripiprazole, and other atypical
antipsychotics. According to new research, Pimavanserin may surpass
other therapy for older people with Parkinson’s disease (PD) psychosis.
Pimavanserin is a powerful inverse agonist with a preference for 5-HT2A
receptors over 5-HT2C receptors and no functional activity at a number
of G-Protein coupled receptors GPRCs such as dopaminergic, muscarinic,
adrenergic, and histaminergic receptors. Pimavanserin had a relative
protective effect in 85 percent of the study group of PD patients living
in the community.